Baxalta US Inc.

650 E. Kendall Street Cambridge, MA 02142 +1 617 588 8800 tel +1 617 588 8210 fax

cc Andy

baxalta.com



## COMMITMENT LETTER Principles for Responsible Clinical Trial Data Sharing

We, leaders of the pharmaceutical industry, believe that:

- Our commitment to data sharing will enhance research and scientific knowledge, advance patient care and improve public health;
- The dramatic increase in the amount of information that research-based companies will make available to researchers will enhance collaborations in the interest of improved research;
- The interests of patients remain at the heart of everything we do in relation to responsible clinical trial data sharing;
- The industry must be allowed to flourish in order to fulfill its promise in serving patients, past, present and future.
- On behalf of Baxalta, I hereby confirm our adherence to the Principles for Responsible Clinical
  Data Sharing launched by PhRMA and EFPIA for medicines/indications approved in the US and
  EU from January 1, 2015 and investigated in clinical trials initiated after July 1, 2015, in which
  patients provide informed consent to use their clinical study data for legitimate academic and
  non-commercial research.

We are therefore committed to:

- Establishing policies, procedures or guidelines to reflect the commitments of the Principles.
- Ensuring that relevant employees have received information and training on the Principles; and
- Considering and planning the steps it will take to monitor compliance with the commitments of the Principles on an ongoing basis.

We also adhere to the EFPIA's decision to ensure that an adequate Certification Scheme is in place by mid-2015, which will allow monitoring and oversight of the companies' compliance with the Principles.

Company: SAXAL	TA
Signed on behalf of the compar	ny by
Name ORLOFF	First name 50HJ
	OBAL HEAD R+D e company in regard of its EFPIA membership obligations
Date 6/15/2015	Signature Would